PLK1 and neoplasm: In this study looked for PLK1-combination targets in non-small cell lung cancer cells (NSCLC), a clinically important tumor type that is driven to a significant degree by mutations in TP53 and KRAS and that as a whole are particularly sensitive to PLK1 inhibition [7].